TherAchon is a biotech company, specialized in research and development for achondroplasia and its associated complications. It is a spin off of the Mediterranean Center of Molecular Medicine, Inserm Unit 1065 based in Nice, France.

Our objective is to develop a recombinant protein therapy for achondroplasia, the most common form of short limb dwarfism. This rare disease affects approximately 1 in 25,000 live births. Children affected by achondroplasia suffer from abnormal long-bone development, resulting in short stature. The most severe cases can suffer from deformations of the skull and vertebrae that can lead to severe neurological and orthopedic complications.

Board of Directors

Michel Mencarelli

Michel is the Director of Marketing & Commercial for EA Pharma in Nice, France. Full Bio »

x

Michel Mencarelli

Michel is the Director of Marketing & Commercial for EA Pharma in Nice, France.

Michel previously served as Director of Commercial Operations for Laboratoires Genevrier and Deputy Director General for their subsidiary, PromoGen. Prior to Laboratoires Genevrier, Michel was Deputy General Manager at Laboratoire LERO and Director of Sales at Pierre Fabre. Michel studied medicine and surgery at the University of Florence in Florence, Italy. Michel is also fluent in French, English and Italian.

Sara Nayeem

Sara joined NEA’s healthcare team in 2009 and focuses on investments in biopharmaceutical companies.

Full Bio »

x

Sara Nayeem

Sara joined NEA’s healthcare team in 2009 and focuses on investments in biopharmaceutical companies.

She serves on the boards of TherAchon, Mersana, Cydan and Vtesse, and as a board observer for Loxo Oncology (LOXO), Ziarco, and Clementia.  She previously served as a board observer for Tesaro (TSRO), Epizyme (EPZM), Omthera (acquired by AstraZeneca), and Zyngenia.  She has also been involved in NEA’s investments in Prosensa (acquired by BioMarin), 3-V Biosciences, Edimer, XTuit, and Proteostasis. Prior to joining NEA, Sara was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions. Previously, she worked as an Investment Banking Analyst at Morgan Stanley. She has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration. Sara concurrently earned her MD (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in Biology from Harvard University.

Stephen Squinto

Stephen Squinto, Ph.D., is a Venture Partner with OrbiMed who brings over 25 years of biotechnology industry experience.

Full Bio »

x

Stephen Squinto

Stephen Squinto, Ph.D., is a Venture Partner with OrbiMed who brings over 25 years of biotechnology industry experience.

Squinto was a co-founder of Alexion Pharmaceuticals, Inc. and recently served as its Executive Vice President and Chief Global Operations Officer. Prior to 2013, he was Alexion’s Global Head of Research and Development.  From 1988 to 1992, Dr. Squinto held various positions at Regeneron Pharmaceuticals, Inc.  Prior to Regeneron, he held a joint academic position at both the Tulane University and LSU Medical Schools.  He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work.  Dr. Squinto received his B.A. in Chemistry and Ph.D. in Biochemistry and Biophysics from Loyola University of Chicago.

Thomas F. Woiwode

Tom has been with Versant Ventures since 2002, serving as a Venture Partner since 2008 and a Managing Director since 2014.

Full Bio »

x

Thomas F. Woiwode

Tom has been with Versant Ventures since 2002, serving as a Venture Partner since 2008 and a Managing Director since 2014.

Tom has served in a number of operating roles over this time, most recently as the Chief Operating Officer of Okairos, a biopharmaceutical company developing genetic vaccines for major infectious diseases. Tom led the process that culminated in the sale of Okairos to GlaxoSmithKline for $325M. Prior to his role with Okairos, Tom co-founded EuroVentures, a wholly owned biotech incubator within Versant Ventures, and in this role, served as the founding Chief Business Officer for three biotech companies created within Versant: Flexion (public), Synosia (public, merged with BioTie), and Amira (acquired by Bristol-Myers Squibb for up to $475M). Prior to his role as a Venture Partner, Tom was a Principal at Versant Ventures and served on the boards of Antipodean, Metabolex and Saegis. Tom was a research scientist at XenoPort before joining Versant. Tom earned his PhD in Organic Chemistry as an NSF Fellow at Stanford University and graduated summa cum laude with a BA in English and received the Departmental Citation for his B.S. in Chemistry from UC Berkeley.

Tom currently serves on the boards of Annapurna, Anokion, Audentes, CRISPR, Gritstone and Therachon.

Our Partners

Latest News

THERACHON SECURES $35 MILLION FINANCING

Strong international syndicate backs promising approach to treat achondroplasia

Therachon, a developer of innovative therapies for achondroplasia, announced today that it closed a $35 million Series A round. The funds will be used to advance Therachon’s lead program, a soluble form of human fibroblast growth factor receptor 3, through clinical proof of concept.

Read More »

Investors

Contact Us

Contact Information

info@therachon.com

Headquarters

TherAchon AG
Aeschenvorstadt 36
4051 Basel
Switzerland

Laboratories

Bâtiment Universitaire
ARCHIMED 151 route
Saint Antoine de Ginestière
BP 2 3194 06204 NICE
CEDEX 03 – France